Amila Patel, PharmD, BCOP, technical lead, Clinical Oncology, Flatiron Health, offers details on new clinical workflow features that will address some of the pain points clinicians have with the electronic medical record system.
Amila Patel, PharmD, BCOP, technical lead, Clinical Oncology, Flatiron Health, offers details on new clinical workflow features that will address some of the pain points clinicians have with the electronic medical record system.
Transcript
What are some new clinical workflow features that clinicians can look forward to in the coming year that will address some of the pain points they have?
Some of the things we’re working on in the coming year that we’re really excited about at Flatiron to introduce into OncoEMR are our visit notes and a redesign experience for how clinicians approach their documentation experience; our clinical inbox, which is how care team members collaborate to view and manage tasks within their inbox workflow; and the last thing we’re working on is a clinical decision support tools called Flatiron Assist that we’re also really excited about.
Does Flatiron take feedback from physicians to help make decisions on what new features should be inlcuded in clinical workflows?
Yes, definitely. We gather feedback from our customers on an ongoing basis. They have the availability to meet with our support teams., But in addition to that, we conduct user research before we start any developmental features to make sure we’re taking the input of our users as we’re developing features.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More